An ongoing open-label phase 1/2 trial (NCT04545736) was initiated in 2020 through the National Eye Institute with an estimated enrollment of 45 patients with ABCA4 retinopathies including STGD1 (Table 1B). The gene discussed is ABCA4; the disease is retinal disorder.